NY‐ESO‐1 antibodies were significantly associated with tumor progression in gastric cancer and esophageal squamous cell carcinoma, while the presence of p53 and/or NY‐ESO‐1 antibodies was significantly associated with poor prognosis only in gastric cancer. Here, TP53 is linked to neoplasm.